Arcutis Biotherapeutics
ARQT
24.17
+0.25
+1.05%
Arcutis Biotherapeutics
US · ARQT
#2465 by market cap
Listed 2020
24.17
+0.25
+1.05%
Live - 5344 symbols - heartbeat 212s ago
· 2026-10-08 07:15
Pre-market
24.22
+0.21%
After-hours
24.17
0.00%
- Market cap
- 3.04B
- P/E (TTM)i
- 109.86
- P/Bi
- 13.77
- EPSi
- -0.13
- Div yieldi
- 0.00%
- 52W posi
- 39%
Reader sentiment
Are you bullish or bearish on ARQT?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 5 analysts
Buy
Avg price target
37.00 +53.1%
Price target rangecurrent 24.17
Low34.00
Avg37.00
High40.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-08-10 | H.C. Wainwright | -- | BUY | 34.00 |
| 2026-08-06 | Morgan Stanley | -- | BUY | 38.00 |
| 2026-08-06 | Needham | -- | BUY | 40.00 |
| 2026-08-06 | H.C. Wainwright | -- | BUY | 34.00 |
| 2026-08-05 | TD Cowen | -- | BUY | 35.00 |
| 2026-08-05 | Guggenheim | -- | BUY | 38.00 |
| 2026-07-16 | Guggenheim | -- | BUY | 35.00 |
| 2026-06-30 | Needham | -- | BUY | 36.00 |
| 2026-05-11 | H.C. Wainwright | -- | BUY | 34.00 |
| 2026-05-07 | TD Cowen | -- | BUY | 35.00 |
| 2026-05-07 | Morgan Stanley | -- | BUY | 34.00 |
| 2026-05-07 | Needham | -- | BUY | 36.00 |
| 2026-05-07 | H.C. Wainwright | -- | BUY | 34.00 |
| 2026-04-23 | TD Cowen | -- | BUY | 35.00 |
| 2026-04-22 | Morgan Stanley | -- | BUY | 35.00 |
| 2026-04-15 | Needham | -- | BUY | 36.00 |
| 2026-03-02 | H.C. Wainwright | -- | BUY | 34.00 |
| 2026-02-27 | Goldman Sachs | -- | HOLD | 33.00 |
| 2026-02-26 | TD Cowen | -- | BUY | 35.00 |
| 2026-02-26 | Morgan Stanley | -- | BUY | 35.00 |
| 2026-02-26 | Needham | -- | BUY | 36.00 |
| 2026-02-26 | Guggenheim | -- | BUY | 35.00 |
| 2026-02-26 | H.C. Wainwright | -- | BUY | 34.00 |
| 2026-02-25 | TD Cowen | -- | BUY | 35.00 |
| 2026-02-02 | H.C. Wainwright | -- | BUY | 30.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
C+
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-05 | After close | ±12.50% | -2.47% (in line) |
| 2026/Q1 | 2026-05-06 | After close | ±9.68% | -14.52% (beat) |
| 2025/Q4 | 2026-02-25 | After close | ±13.18% | +5.78% (in line) |
| 2025/Q3 | 2025-10-28 | -- | ±15.85% | +27.04% (beat) |
| 2025/Q2 | 2025-08-06 | After close | ±14.21% | -8.07% (in line) |
| 2025/Q1 | 2025-05-06 | After close | ±18.89% | -4.33% (in line) |
| 2024/Q4 | 2025-02-25 | After close | ±25.48% | +8.36% (in line) |
| 2024/Q3 | 2024-11-06 | After close | ±20.13% | +7.66% (in line) |
| 2024/Q2 | 2024-08-14 | After close | ±17.75% | -11.27% (in line) |
| 2024/Q1 | 2024-05-14 | After close | ±33.32% | +13.65% (in line) |
| 2023/Q4 | 2024-02-27 | -- | ±31.15% | +9.70% (in line) |
| 2023/Q3 | 2023-11-03 | -- | ±27.93% | +9.91% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:15:25 · For reference only, not investment advice and not tailored to your situation.